xCures has partnered to make the xINFORM patient portal available to PanCAN’s Patient Services program and longitudinal clinical data from the xCures database accessible to PanCAN’s grantees and clinical researchers
Research Partners
Cancer drug repurposing project with CDRC
xCures has partnered with the Critical Path Institute and the CURE Drug Repurposing Collaboratory (CDRC) to search for efficacious uses of repurposed drugs by generating regulatory-compliant real-world data in sarcomas
Natural history study inDIPG/DMG (xPedite)
xCures has partnered with the DIPG and DMG Research Funding Alliance (DDRFA) to support the recruitment of patients with these rare CNS cancers into a natural history study (xPedite) with the
ultimate goal of ending randomization in clinical trials.
Fibrolamellar observational research platform
The FibroFighters Foundation and xCures have partnered to create a complete longitudinal clinical data registry in fibrolamellar carcinoma, a rare form of liver cancer primarily affecting adolescents and young adults.
Cancer Commons
Cancer Commons is a nonprofit that provides hope to advanced cancer patients by offering a highly customized and personal experience and helping them quickly identify and access their best possible treatment.
Expanded Access Program – Ulixertinib
xCures partnered with BioMed Valley Discoveries to offer expanded access to ulixertinib, a first-in-class ERK1/2 inhibitor, for patients with advanced solid tumors who are no longer responding to or have exhausted standard of care. Detailed inclusion/exclusion criteria can be found at clinicaltrials.gov.
PROMAP – Medical Food Study
xCures has partnered with a new oncology company specializing in a metabolic approach to cancer treatment. Their PROMAP study is testing a special diet designed to improve responses to standard-of-care chemotherapy in pancreatic cancer.
POETIC
xCures collaborates with POETIC, a non-profit organization that manages pediatric oncology early phase trials, to get children, adolescents, and young adults with cancer enrolled in expanded access programs of promising therapies.
TAPUR™ Study
xCures’ treatment options include, where applicable, therapies on the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. TAPUR is a clinical trial for patients with advanced cancer who have not responded to standard treatment or are without available standard treatment options and who have genomic alterations in their tumors that can be targeted with a commercially available anticancer drug.